Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary nonbullous or bullous impetigo.
Epistemonikos ID: 9bf06f643a9714256c023b3a8f78e370e095250d
First added on: May 21, 2024